Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Biotechnology save search
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Published: 2023-10-31 (Crawled : 14:00) - biospace.com/
ADAP | $0.9978 -3.13% -3.23% 1.2M
|
Health Technology
|
| O: 2.7%
H: 2.23%
C: -5.14%
positive trial
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
Published: 2023-09-19 (Crawled : 12:00) - biospace.com/
BGNE S | $131.885 -1.62% -1.64% 200K
|
Health Technology
|
| O: 0.16%
H: 1.03%
C: -0.19%
tevimbra europe positive global
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: 8.13%
H: 0.95%
C: -4.58%
rare disease mrna positive results
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
Published: 2023-09-05 (Crawled : 12:00) - biospace.com/
NUVL | $64.19 -0.87% -0.89% 590K
|
|
| O: -0.06%
H: 3.79%
C: 3.04%
tumors trial
FDA Approves J&J’s Akeega for BRCA-Positive Prostate Cancer
Published: 2023-08-14 (Crawled : 12:20) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
fda cancer
Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-07-13 (Crawled : 16:00) - biospace.com/
SKYE | $9.17 -20.98% 27K
|
Transportation and Warehousing
|
| O: -6.1%
H: 6.5%
C: 4.5%
sbi-100 review positive bioscience study
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line
Published: 2023-05-18 (Crawled : 22:00) - biospace.com/
CELZ | $4.91 -5.58% -5.91% 19K
|
|
| O: 6.06%
H: 2.71%
C: -15.41%
stemspine back positive cell medical technology results study
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: 0.0%
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 20.4%
H: 26.64%
C: 6.13%
covid vaccine positive influenza topline results show
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Published: 2023-05-08 (Crawled : 22:00) - biospace.com/
ENTA | News | $14.005 -8.82% -9.68% 190K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: -4.74%
edp-235 covid-19 positive risk pharmaceuticals topline trial results
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
Published: 2023-04-26 (Crawled : 13:20) - biospace.com/
INO 2 d | $11.05 14.69% 12.81% 700K
|
Health Technology
|
| O: -0.18%
H: 2.4%
C: -1.56%
ino-3107 drug positive designation application
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study
Published: 2023-04-12 (Crawled : 18:00) - biospace.com/
CELZ | $4.91 -5.58% -5.91% 19K
|
|
| O: 160.33%
H: 5.56%
C: -30.56%
positive medical technology diabetes results study
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
TLSA | $0.552 0.27% 0.27% 95K
|
Health Technology
|
| O: 0.49%
H: 2.94%
C: -21.56%
anti-cd3 antibody positive
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Published: 2023-03-31 (Crawled : 17:00) - biospace.com/
IMMP | News | $2.255 -0.22% -0.22% 200K
|
Health Technology
|
| O: 2.91%
H: 0.56%
C: -5.08%
lung positive cancer therapy
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
INO 2 d | $11.05 14.69% 12.81% 700K
|
Health Technology
|
| O: 2.99%
H: 8.72%
C: 4.07%
ino-4201 ervebo ebola positive phase 2b
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
Published: 2022-12-13 (Crawled : 13:00) - biospace.com/
CLLS | $2.48 -0.4% -0.4% 6.9K
|
Health Technology
|
| O: 5.83%
H: 5.93%
C: -0.85%
ucart22 aml ucart123 positive
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
Published: 2022-12-07 (Crawled : 23:00) - biospace.com/
DSGN | $3.95 7.05% 6.58% 420K
|
Professional, Scientific, and T...
|
| O: -0.59%
H: 3.87%
C: -5.44%
dt-216 treatment trial therapeutics positive friedreich’s ataxia
INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
Published: 2022-10-13 (Crawled : 13:20) - biospace.com/
INO 2 d | $11.05 14.69% 12.81% 700K
|
Health Technology
|
| O: -3.68%
H: 8.92%
C: 8.28%
ino-3107 treatment respiratory positive phase 1
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
SCYX | $1.42 0.71% 0.7% 130K
|
Health Technology
|
| O: -0.39%
H: 12.4%
C: 4.26%
positive study
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure
Published: 2022-09-28 (Crawled : 22:00) - biospace.com/
WINT | News | $0.3903 -7.4% -7.99% 110K
|
Health Technology
|
| O: 2.37%
H: 5.62%
C: 0.09%
heart therapeutics positive study phase 2
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study
Published: 2022-09-26 (Crawled : 16:00) - biospace.com/
CELZ | $4.91 -5.58% -5.91% 19K
|
|
| O: -0.91%
H: 5.97%
C: -10.62%
stemspine technology positive publication study
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.